Vertex Pharma (VRTX) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $530.76 --0%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $0.35, $0.06 better than the analyst estimate of $0.29. Revenue for the quarter came in at $458.71 versus the consensus estimate of $453.4 million.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
- Option Care Health (OPCH) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
